An Exploratory Study on Efficacy of Anlotinib Hydrochloride in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer
Latest Information Update: 25 Apr 2023
At a glance
- Drugs Catequentinib (Primary)
- Indications Thyroid cancer
- Focus Pharmacokinetics
- 17 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2022 Planned End Date changed from 7 Dec 2022 to 7 Dec 2023.
- 18 Jan 2022 Planned primary completion date changed from 7 Dec 2021 to 7 Dec 2023.